Affinage

SLC7A11

Cystine/glutamate transporter · UniProt Q9UPY5

Length
501 aa
Mass
55.4 kDa
Annotated
2026-06-10
100 papers in source corpus 42 papers cited in narrative 42 extracted findings
Cross-family judge vs UniProt: Affinage preferred faithfulness: 6/7 claims corpus-supported (86%)

Mechanistic narrative

Synthesis pass · prose summary of the discoveries below

SLC7A11 (xCT) is the substrate-specific light-chain subunit of the plasma-membrane cystine/glutamate antiporter system xc-, disulfide-linked to the heavy chain 4F2hc/SLC3A2, exchanging extracellular cystine for intracellular glutamate to supply cysteine for glutathione synthesis and antioxidant defense (PMID:21369940). Through this function it is the central cellular determinant of ferroptosis sensitivity: high SLC7A11 maintains GSH and suppresses lipid peroxidation, while its loss or inhibition triggers ferroptotic death across diverse tissues including cardiomyocytes, hepatocytes, and tumors (PMID:32349646, PMID:36996941). Beyond the cell surface, SLC7A11 also resides on lysosomes where downward flux of cystine and glutamate mediates a slow H+ leak that regulates lysosomal pH and degradative capacity; its deficiency causes over-acidification, impaired degradation, and facilitates α-synuclein aggregation in neurons (PMID:40280132). SLC7A11 abundance and activity are governed by an exceptionally dense post-translational network: K48/K11-linked polyubiquitination by E3 ligases SOCS2, TRIM3, and ZRANB1 drives proteasomal degradation (PMID:35995846, PMID:37978273, PMID:37831441), while deubiquitinases USP52 and DUBA, S-palmitoylation at Cys327 by AMPKα1-activated ZDHHC8, O-GlcNAcylation at Ser26 by OGT (essential for cystine import), and PIAS4-mediated SUMOylation stabilize the protein or its transport function (PMID:39392373, PMID:38211651, PMID:37867237, PMID:38615741, PMID:37537342). Membrane delivery requires SPTBN2-Arp1 trafficking, and surface localization is antagonized by secreted Galectin-13 acting through CD44 to propagate ferroptosis to neighboring cells (PMID:38241838, PMID:40246981). Transcriptionally, SLC7A11 is activated by ATF4, SOX2, CEBPG, NFATc1, STAT6, and AhR and repressed by the BAP1/PRC1 H2A-ubiquitination axis, EZH2/H3K27me3, and CIC (PMID:36996941, PMID:34385181, PMID:37210575, PMID:30907299, PMID:34615538, PMID:36647117), and its mRNA is further tuned by RNA-binding proteins (RBMS1, DAZAP1) and m6A machinery (METTL3/IGF2BP1/2, FTO/YTHDF2, ALKBH5) (PMID:34609966, PMID:35522946, PMID:36820954, PMID:39799112). Functionally, SLC7A11 imports kynurenine to propagate anti-ferroptotic NRF2 signaling, acts as a metabolic brake on dendritic-cell efferocytosis, and regulates CNS extracellular glutamate; excessive cystine uptake under thioredoxin-reductase inhibition can instead drive disulfidptosis (PMID:35245456, PMID:35614212, PMID:37148740, PMID:36647117).

Mechanistic history

Synthesis pass · year-by-year structured walk · 15 steps
  1. 2011 High

    Established the core biochemical identity of SLC7A11 as the cystine/glutamate antiporter light chain, defining how it supplies the rate-limiting precursor for glutathione synthesis.

    Evidence Synthesis of transport assays, disulfide-linkage biochemistry, and pharmacological inhibition in neuronal systems

    PMID:21369940

    Open questions at the time
    • Did not resolve the transporter's role in regulated cell death
    • Structural basis of cystine/glutamate exchange not addressed
  2. 2019 High

    Connected SLC7A11 transcriptional suppression to immunotherapy and radiotherapy efficacy, establishing it as a therapeutically targetable node controlling tumor ferroptosis.

    Evidence In vivo tumor models with IFNγ neutralization, ATM inhibition, and ferroptosis modulation

    PMID:31554642

    Open questions at the time
    • Direct transcription factors downstream of IFNγ/ATM at the SLC7A11 promoter not fully mapped
  3. 2019 High

    Defined epigenetic and surface-protein control of SLC7A11, showing BAP1-mediated H2A deubiquitination represses transcription while CD44v8-10 stabilizes surface protein to govern antioxidant defense.

    Evidence ChIP for H2Aub, BAP1/PRC1 genetic manipulation, ferroptosis assays; cell-surface xCT quantification and GSH measurement in EndMT/PAH models

    PMID:30897333 PMID:30907299

    Open questions at the time
    • Direct physical CD44v-xCT interaction inferred rather than mapped in [#33]
    • How dynamic H2Aub balance is set at the promoter not resolved
  4. 2020 High

    Demonstrated in vivo that SLC7A11 sustains GSH to prevent iron-overload ferroptosis in cardiomyocytes, extending its protective role beyond cancer to organ physiology.

    Evidence Cardiomyocyte-specific conditional KO and overexpression with ferrostatin-1 rescue

    PMID:32349646

    Open questions at the time
    • Upstream regulators of cardiac SLC7A11 not defined
    • Did not address lysosomal function
  5. 2020 Medium

    Opened the mRNA-stability layer of SLC7A11 regulation, showing 3'UTR-binding RBPs tune transcript abundance and thereby ferroptosis sensitivity.

    Evidence RIP, 3'UTR binding and mRNA stability assays for DAZAP1 in HCC

    PMID:33358859

    Open questions at the time
    • Single Co-IP/RIP without reciprocal validation
    • Direct binding motif not mapped
  6. 2021 High

    Identified ubiquitin-dependent degradation of SLC7A11 by E3 ligase SOCS2, establishing the first substrate-receptor mechanism targeting the transporter for proteasomal turnover.

    Evidence Co-IP with domain mapping (SH2/SOCS-BOX), elongin B/C recruitment, ubiquitination assays, in vivo radiosensitivity models

    PMID:35995846

    Open questions at the time
    • Counteracting deubiquitinases for SOCS2-driven chains not identified here
    • Physiological trigger for SOCS2 engagement unclear
  7. 2021 High

    Revealed translational control of SLC7A11, with RBMS1 bridging 5'/3'-UTRs via eIF3d to enhance translation and govern cystine uptake.

    Evidence shRNA screen, RIP, translation and eIF3d pulldown assays, cystine uptake, in vivo lung cancer models

    PMID:34609966

    Open questions at the time
    • Signals controlling RBMS1 activity not defined
  8. 2021 Medium

    Expanded epigenetic and post-translational regulation, showing histone-modification enzymes (EZH2/H3K27me3, KDM4A/H3K9me3), SOX2 transcriptional activation, miRNA axes, and UFMylation each set SLC7A11 levels.

    Evidence ChIP for histone marks, promoter-reporter and binding-site mutagenesis, dual-luciferase miRNA assays, UFMylation IP and stability assays

    PMID:33689883 PMID:34162423 PMID:34385181 PMID:34614259 PMID:34615538

    Open questions at the time
    • Several axes rest on single-lab reporter assays
    • Hierarchy among competing transcriptional inputs unresolved
    • UFM1 ligase machinery for SLC7A11 not identified
  9. 2022 High

    Established non-canonical signaling and immunometabolic roles: SLC7A11 imports kynurenine to propagate NRF2-dependent anti-ferroptotic signaling and acts as a metabolic brake on dendritic-cell efferocytosis.

    Evidence Genetic KO of SLC7A11/IDO1 with metabolite rescue and NRF2/AHR dissection; pharmacological/genetic SLC7A11 ablation, metabolic flux, db/db wound-healing model

    PMID:35245456 PMID:35614212

    Open questions at the time
    • Structural basis for kynurenine transport by SLC7A11 not defined
    • Link between transporter activity and glycolytic rewiring mechanistically incomplete
  10. 2022 Medium

    Defined the m6A and RBP layer of mRNA stability control, with METTL3/IGF2BP1 blocking deadenylation and PCBP2 (stabilized by PHGDH) and additional factors setting transcript half-life.

    Evidence MeRIP, RIP, RNA pulldown, deadenylation (RACE-PAT) and mRNA stability assays

    PMID:35086885 PMID:35522946 PMID:36147463

    Open questions at the time
    • Single-lab mechanisms not cross-validated
    • Interplay among multiple m6A writers/readers on the same transcript unresolved
  11. 2023 High

    Mapped specific ubiquitin linkages and lysine sites for SLC7A11 degradation (TRIM3 K11/K37, ZRANB1) and opposing deubiquitination/stabilization (DUBA, OGT O-GlcNAcylation at Ser26 with USP8/SLK control), defining a precise PTM grammar for transporter turnover and activity.

    Evidence Co-IP, domain mapping, linkage- and site-specific ubiquitination and O-GlcNAcylation assays, mass spectrometry, functional rescue, in vivo xenografts

    PMID:37537342 PMID:37831441 PMID:37867237 PMID:37978273

    Open questions at the time
    • Cross-talk between distinct ubiquitin linkages on SLC7A11 not integrated
    • Physiological cues directing each ligase/DUB to the substrate unclear
  12. 2023 Medium

    Broadened transcriptional regulation across tissues (ATF4, CEBPG, NFATc1, STAT6, AhR, CIC) and tied SLC7A11 to distinct death modalities, including NFATc1-driven disulfidptosis in osteoclast precursors and CIC-controlled CNS glutamate release.

    Evidence Tissue-specific KO/rescue, ChIP/CUT&Tag, promoter-reporter, p53-acetylation and 14-3-3/phospho-mutant analyses, death-modality inhibitor panels, in vivo disease models

    PMID:35668064 PMID:36647117 PMID:36996941 PMID:37148740 PMID:37210575 PMID:38641223

    Open questions at the time
    • Several transcriptional axes are single-lab
    • Conditions that switch SLC7A11 output between ferroptosis protection and disulfidptosis vulnerability not unified
  13. 2024 High

    Resolved palmitoylation- and SUMOylation-based stabilization (AMPKα1-ZDHHC8-Cys327; PIAS4) and deubiquitinase USP52 control, plus trafficking by SPTBN2-Arp1 as a prerequisite for surface transport activity.

    Evidence Acyl-RAC palmitoylation and SUMOylation assays, site-specific mutagenesis (Cys327), DUB siRNA screen, Co-IP/membrane fractionation, in vivo models

    PMID:38211651 PMID:38241838 PMID:38615741 PMID:39392373

    Open questions at the time
    • Interplay between palmitoylation, ubiquitination, and trafficking not temporally ordered
    • Some interactions (SPTBN2, PIAS4) rest on single-lab Co-IP
  14. 2024 Medium

    Extended mRNA and protein regulation through additional m6A enzymes and RBPs (FTO/YTHDF2, FMRP/hnRNPM splicing, METTL3/IGF2BP2 and METTL3/YTHDF2/SOCS2) and identified NINJ1 as a physical interactor limiting xCT stability.

    Evidence m6A site mapping, RIP, splicing and stability assays, Co-IP, ubiquitination assays, in vivo models

    PMID:38600610 PMID:39388855 PMID:39424803 PMID:39799112

    Open questions at the time
    • Multiple parallel m6A mechanisms not reconciled
    • NINJ1-xCT mechanism rests on single-lab Co-IP
  15. 2025 High

    Discovered an organelle-level function—lysosomal H+ leak via SLC7A11 controlling lysosomal pH, degradation, and neuronal α-synuclein aggregation—and a non-cell-autonomous ferroptosis propagation circuit through secreted Galectin-13/CD44 inhibition of xCT membrane localization.

    Evidence Orphan lysosomal-protein screen, KO/inhibition, lysosomal pH measurement and rescue; Galectin-13 secretion, CD44 Co-IP, membrane fractionation, FOXK1/PKCβII phosphorylation, mimetic-peptide assays

    PMID:40246981 PMID:40280132

    Open questions at the time
    • Structural mechanism of lysosomal H+ leak vs plasma-membrane antiport not defined
    • How surface vs lysosomal pools are partitioned and regulated unknown

Open questions

Synthesis pass · forward-looking unresolved questions
  • How the dozens of competing transcriptional, RNA-level, and post-translational inputs are integrated to set SLC7A11 surface vs lysosomal abundance in a given cell state, and the structural basis distinguishing its antiport, kynurenine import, and lysosomal H+-leak functions, remain unresolved.
  • No unified model of regulatory hierarchy
  • No structure linking transport modes
  • Determinants of plasma-membrane vs lysosomal localization unknown

Mechanism profile

Synthesis pass · controlled-vocabulary classification · explore literature graph →
Molecular activity
GO:0005215 transporter activity 5 GO:0140104 molecular carrier activity 2
Localization
GO:0005886 plasma membrane 4 GO:0005764 lysosome 2
Pathway
R-HSA-5357801 Programmed Cell Death 5 R-HSA-1430728 Metabolism 3 R-HSA-8953897 Cellular responses to stimuli 2
Partners
CD44SLC3A2SOCS2SPTBN2TRIM3USP52ZDHHC8ZRANB1
Complex memberships
system xc- (SLC7A11/SLC3A2 antiporter)

Evidence

Reading pass · 42 per-paper findings extracted from the source corpus
Year Finding Method Journal Conf PMIDs
2025 SLC7A11 mediates a slow lysosomal H+ leak by downward flux of cystine and glutamate (two H+ equivalents with large but opposite concentration gradients across lysosomal membranes). SLC7A11 deficiency or inhibition caused lysosomal over-acidification, reduced degradation, accumulation of storage materials, ferroptosis, and facilitated α-synuclein aggregation in neurons; correction of abnormal lysosomal acidity restored lysosome homeostasis. Candidate screen on orphan lysosome membrane protein library, genetic KO/inhibition of SLC7A11, lysosomal pH measurements, organelle fractionation, live imaging, neuronal models Cell High 40280132
2011 SLC7A11/xCT forms the light-chain subunit of system xc-, linked by a disulfide bridge to the heavy chain 4F2hc (SLC3A2), and mediates 1:1 exchange of extracellular cystine for intracellular glutamate; intracellularly, cystine is reduced to cysteine, the rate-limiting precursor of glutathione. Regulation extends to membrane trafficking and modulation by extracellular glutamate transport. Review of functional transport assays, disulfide-linkage biochemistry, pharmacological inhibition, and neuronal cell-line studies summarized Amino acids High 21369940
2019 IFNγ derived from immunotherapy-activated CD8+ T cells and radiotherapy-activated ATM independently yet synergistically suppress SLC7A11 transcription, reducing cystine uptake and enhancing tumor-cell lipid oxidation and ferroptosis. In vivo tumor models, genetic/pharmacological ferroptosis modulation, IFNγ neutralization, ATM inhibition, gene expression analysis Cancer discovery High 31554642
2019 Tumor suppressor BAP1, a H2A deubiquitinase, represses SLC7A11 expression by reducing H2A ubiquitination (H2Aub) on the SLC7A11 promoter; BAP1 inactivation leads to SLC7A11 de-repression and ferroptosis resistance. PRC1 (major H2Aub ligase) also represses SLC7A11, indicating dynamic H2Aub regulation is required for repression. BAP1-mediated ferroptosis induction is through SLC7A11 (class I FIN erastin) but not class II FIN RSL3. ChIP for H2Aub at SLC7A11 promoter, BAP1 KO/KD, PRC1 manipulation, ferroptosis assays with class I and II FINs Cell cycle (Georgetown, Tex.) High 30907299
2021 SOCS2 directly binds the N-terminal domain of SLC7A11 via its SH2 domain, and uses its SOCS-BOX (L162, C166) to recruit an elongin B/C complex; this SOCS2/elongin B/C complex transfers ubiquitin to SLC7A11, promoting K48-linked polyubiquitination degradation of SLC7A11 and triggering ferroptosis. Co-IP, domain mapping, ubiquitination assays, in vivo xenograft radiosensitivity models, ferroptosis markers (lipid peroxidation, Fe2+) Cell death and differentiation High 35995846
2021 RNA-binding protein RBMS1 directly interacts with translation initiation factor eIF3d and bridges the 3'- and 5'-UTR of SLC7A11 mRNA to enhance its translation; RBMS1 ablation inhibits SLC7A11 translation, reducing cystine uptake and promoting ferroptosis. shRNA screen, RIP, translation assay, eIF3d pulldown, cystine uptake assay, in vivo lung cancer models The Journal of clinical investigation High 34609966
2021 UFM1-mediated UFMylation of SLC7A11 promotes its protein stability; metformin inhibits this UFMylation, thereby reducing SLC7A11 protein levels, increasing intracellular Fe2+ and lipid ROS, and inducing ferroptosis in breast cancer cells. Co-IP/immunoprecipitation for UFMylation detection, SLC7A11 protein stability assays, ferroptosis markers (Fe2+, lipid ROS, GSH), in vivo nude-mouse tumor model Journal of experimental & clinical cancer research : CR Medium 34162423
2023 TRIM3 E3 ubiquitin ligase directly interacts with SLC7A11 through its NHL domain and promotes SLC7A11 K11-linked ubiquitination at K37, leading to proteasome-mediated degradation of SLC7A11 and ferroptosis induction in NSCLC. Co-IP, domain mapping (NHL domain), ubiquitination assay (K11-linkage, K37 site), proteasome inhibitor rescue, in vivo tumor xenograft Cell death and differentiation High 37978273
2023 ZRANB1 functions as an E3 ubiquitin ligase (not a deubiquitinase) for SLC7A11: it ubiquitinates and represses SLC7A11, inhibiting glutathione synthesis and promoting ferroptosis. Deletion of residues 463–584 abolishes ZRANB1's E3 activity. Whole-DUB sgRNA screen, ubiquitination assay, domain deletion mutagenesis, GSH/lipid peroxidation assays The Journal of cell biology High 37831441
2024 USP52/PAN2 deubiquitylase interacts with SLC7A11/xCT and cleaves K48-linked ubiquitin chains at K4 and K12 of SLC7A11, thereby enhancing its protein stability and ferroptosis resistance in bladder cancer. siRNA screen of 96 DUBs, Co-IP, ubiquitin chain linkage analysis, site-specific mutagenesis (K4, K12), GSH/lipid peroxidation assays, in vivo xenograft Advanced science (Weinheim, Baden-Wurttemberg, Germany) High 39392373
2024 AMPKα1 directly phosphorylates ZDHHC8 at S299, strengthening ZDHHC8-SLC7A11 interaction; ZDHHC8 then catalyzes S-palmitoylation of SLC7A11 at Cys327, reducing its ubiquitination and stabilizing SLC7A11 protein to confer ferroptosis resistance in glioblastoma. Co-IP, phospho-site mutagenesis (S299), palmitoylation assay (acyl-RAC), Cys327 mutagenesis, ubiquitination assay, ZDHHC8 KD rescue with SLC7A11 OE Cancer letters High 38211651
2023 OGT O-GlcNAcylates SLC7A11 at Ser26, a modification essential for SLC7A11 cystine import activity; USP8 stabilizes OGT by inhibiting K48-linked polyubiquitination at OGT K117, and SLK-mediated S716 phosphorylation of USP8 is required for USP8-OGT interaction. Co-IP, mass spectrometry, site-specific mutagenesis (Ser26, K117, S716), OGT KO rescue assay, cystine uptake assay, GSH measurement Advanced science (Weinheim, Baden-Wurttemberg, Germany) High 37867237
2022 Kynurenine (KYN), exported from IDO1-expressing cells, is imported by SLC7A11 into non-IDO1-expressing neighboring cells; intracellular KYN-derived metabolites suppress ferroptosis by ROS scavenging and activation of an NRF2-dependent, AHR-independent cell-protective pathway that includes SLC7A11 upregulation, propagating anti-ferroptotic signaling. Genetic KO of SLC7A11 and IDO1, metabolite supplementation, NRF2/AHR pathway analysis, ferroptosis assays Molecular cell High 35245456
2022 SLC7A11 acts as a molecular brake on efferocytosis in dendritic cells; pharmacological inhibition, deletion, or siRNA knockdown of Slc7a11 enhanced efferocytosis. Mechanistically, SLC7A11-deficient DCs became dependent on aerobic glycolysis using glucose from glycogen stores. In a diabetic wound-healing model, loss of SLC7A11 accelerated wound healing and reduced apoptotic cell load, linked to GDF15 release from efferocytic DCs. Pharmacological inhibition of SLC7A11, genetic KO, siRNA KD, transcriptomics of efferocytic DCs, db/db mouse wound model, metabolic flux studies Nature High 35614212
2020 Slc7a11 deficiency in Fth-knockout cardiomyocytes reduces glutathione levels; overexpressing Slc7a11 selectively in cardiomyocytes increased GSH levels and prevented cardiac ferroptosis induced by iron overload. Conditional cardiomyocyte-specific KO (MCK-Cre, Myh6-Cre), Slc7a11 overexpression, GSH measurement, lipid peroxidation assay, ferrostatin-1 rescue Circulation research High 32349646
2023 ATF4 directly activates SLC7A11 transcription; SLC7A11 maintains glutathione production to inhibit ferroptosis in hepatocytes. ATF4 ablation decreased SLC7A11 expression and increased ferroptosis susceptibility; ectopic SLC7A11 expression in ATF4-deficient hepatocytes and mouse livers reversed ferroptosis and hepatocarcinogenesis. Hepatocyte-specific ATF4 KO, ectopic SLC7A11 reconstitution in KO cells/mice, GSH measurement, lipid peroxidation assays, RNA-sequencing, HCC mouse models Journal of hepatology High 36996941
2021 HBx protein promotes EZH2-mediated H3K27me3 modification at the SLC7A11 promoter, suppressing SLC7A11 transcription and facilitating ferroptosis in hepatocytes; EZH2 inhibition or SLC7A11 overexpression rescued HBx-induced ferroptosis. ChIP for H3K27me3 at SLC7A11 promoter, Co-IP for HBx-EZH2 interaction, EZH2 inhibition, SLC7A11 OE rescue, ferroptosis markers (GSH, MDA, iron) Journal of biomedical science Medium 34615538
2021 KDM4A histone demethylase removes H3K9me3 from the SLC7A11 promoter, increasing SLC7A11 transcription and inhibiting ferroptosis in osteosarcoma; KDM4A knockdown reduced SLC7A11 expression and promoted ferroptosis. ChIP for H3K9me3 at SLC7A11 promoter, KDM4A KD, ferroptosis markers, in vivo metastasis model Biochemical and biophysical research communications Medium 33689883
2021 SOX2 directly binds the SLC7A11 promoter to activate its transcription; mutation of the SOX2 binding site in the SLC7A11 promoter reduced SLC7A11 expression and increased ferroptosis sensitivity. Oxidation at Cys265 of SOX2 inhibited its transcriptional activity toward SLC7A11. SLC7A11 promoter-reporter assay, SOX2 binding-site mutagenesis, Cys265 mutagenesis, ferroptosis assays, lung cancer stem-like cell models Cancer research High 34385181
2023 NFATc1 transcriptionally upregulates SLC7A11 during RANKL-induced osteoclastogenesis; elevated SLC7A11 increases cystine transport leading to cystine accumulation upon TXNRD1 inhibition, causing disulfidptosis (not ferroptosis) specifically in osteoclast precursors. ChIP/transcriptional reporter for NFATc1-SLC7A11, SLC7A11 inhibitors, ferroptosis vs. disulfidptosis inhibitor panel, in vivo OVX mouse model, bone cystine measurement Redox biology Medium 37148740
2022 METTL3-mediated m6A modification of SLC7A11 mRNA is read by IGF2BP1, which competitively binds PABPC1 to block BTG2/CCR4-NOT complex recruitment, thereby inhibiting SLC7A11 mRNA deadenylation and enhancing mRNA stability and expression in hepatoblastoma. MeRIP-qPCR, RNA pulldown, RIP, RACE-PAT (deadenylation assay), dual luciferase reporter, m6A quantification Clinical and translational medicine High 35522946
2022 PHGDH binds to RNA-binding protein PCBP2 and inhibits its ubiquitination degradation; stabilized PCBP2 in turn stabilizes SLC7A11 mRNA, increasing SLC7A11 expression and inhibiting ferroptosis in bladder cancer. Co-IP, mass spectrometry, RIP assay, ubiquitination assay, SLC7A11 mRNA stability assay International journal of biological sciences Medium 36147463
2020 RNA-binding protein DAZAP1 interacts with the 3'UTR of SLC7A11 mRNA and positively regulates its stability, thereby inhibiting ferroptosis in HCC. RNA immunoprecipitation (RIP), 3'UTR binding assay, mRNA stability assay, ferroptosis assays Experimental cell research Medium 33358859
2022 CEBPG directly binds the SLC7A11 promoter and transcriptionally activates SLC7A11 expression to suppress ferroptosis in ovarian cancer. CUT&Tag chromatin profiling, dual luciferase reporter assay, CEBPG KD, RNA-sequencing, ferroptosis assays, orthotopic mouse model Journal of translational medicine Medium 37210575
2021 EZH2 promotes SLC7A11 expression by repressing miR-125b-5p (which targets SLC7A11 3'UTR), thereby inhibiting ferroptosis in tongue squamous cell carcinoma; dual-luciferase assays confirmed EZH2 binding to miR-125b-5p promoter and miR-125b-5p binding to SLC7A11 3'UTR. Dual-luciferase reporter assays, RT-qPCR, Western blot, CCK-8, MDA assay Oral diseases Medium 34614259
2022 ALKBH5 erases m6A modification on SLC7A11 mRNA, reducing its stability and expression, thereby promoting ferroptosis in colorectal cancer cells. m6A quantitative analysis, MeRIP-qPCR, mRNA stability assay (actinomycin D), ALKBH5 OE and SLC7A11 OE rescue, in vivo xenograft Clinical & translational oncology Medium 36820954
2024 FTO m6A demethylase increases SLC7A11 expression in an m6A-YTHDF2-dependent manner; high FTO stabilizes SLC7A11 mRNA, counteracting ferroptosis in colorectal cancer. m6A modification analysis, YTHDF2 interaction studies, SLC7A11 mRNA stability assay, FTO KD/OE, in vivo CRC models Journal of experimental & clinical cancer research : CR Medium 38600610
2023 STAT6 competes with the acetyltransferase CBP to inhibit p53 acetylation, thereby transcriptionally restoring SLC7A11 expression and suppressing ferroptosis in lung epithelial cells during acute lung injury. ChIP, Co-IP for STAT6-CBP interaction, p53 acetylation assay, STAT6 KD/OE, SLC7A11 promoter-reporter, lung-specific STAT6 OE in ALI mouse models Cell death & disease Medium 35668064
2024 SPTBN2 interacts with SLC7A11 through its CH domain and connects it with motor protein Arp1, facilitating SLC7A11 membrane localization—a prerequisite for its cystine-uptake/GSH-synthesis function as System Xc-; SPTBN2 inhibition reduces membrane SLC7A11 and sensitizes NSCLC to ferroptosis. Co-IP (SPTBN2-SLC7A11-Arp1), membrane fractionation, ferroptosis assays (lipid ROS, GSH), in vivo cisplatin sensitivity model Redox biology Medium 38241838
2025 Galectin-13 secreted from ferroptotic cells binds CD44 on neighboring cells and inhibits SLC7A11 plasma membrane localization, thereby reducing cystine uptake and propagating ferroptosis to neighboring cells. FOXK1, phosphorylated by PKCβII, drives Galectin-13 expression and secretion during ferroptosis. Galectin-13 secretion measurement, Co-IP (Galectin-13 with CD44), SLC7A11 membrane localization by fractionation/imaging, FOXK1 phosphorylation assay, functional ferroptosis propagation assays, synthetic mimetic peptide experiments Nature chemical biology High 40246981
2024 NINJ1 physically interacts with the xCT antiporter (SLC7A11); NINJ1 knockdown increases xCT protein levels and stability, enhancing cystine uptake, CoA, and GSH levels, thereby protecting against ferroptosis induced by xCT inhibitors specifically. Co-IP (NINJ1-xCT), NINJ1 KD/OE, xCT protein stability assay, cystine uptake assay, compound screen (PANKi, BSO, DEM), ferroptosis assays Cell death & disease Medium 39424803
2024 Tumor suppressor BAP1 (H2A deubiquitinase) suppresses disulfidptosis through repression of SLC7A11: BAP1 suppresses SLC7A11 expression; SLC7A11 overexpression or additional cystine counteracts BAP1's protection against disulfidptosis; conversely, BAP1-mediated suppression of disulfidptosis is abrogated when SLC7A11-mediated cystine uptake is genetically or pharmacologically blocked. SLC7A11 KO/OE, disulfide bond accumulation assay (cytoskeleton proteins), cell death inhibitor panel, cystine supplementation, BAP1 OE Oncogenesis Medium 39266549
2023 CIC (Capicua) transcriptionally represses SLC7A11/xCT expression; non-phosphorylatable CIC (S173) that cannot interact with 14-3-3 showed stronger repressor function; CIC restoration in an oligodendroglioma line reduced SLC7A11 levels and extracellular glutamate release. CIC KO/re-expression, RNA-sequencing, extracellular glutamate measurement, CIC-S173 phospho-mutant analysis, 14-3-3 interaction studies Acta neuropathologica communications Medium 36647117
2019 CD44 variant (CD44v8-10) stabilizes xCT/SLC7A11 protein on the cell surface, promoting reduced glutathione production and antioxidant defense; during endothelial-to-mesenchymal transition (EndMT), CD44v+ cells co-express high xCT and show enhanced survival dependent on this axis. Cell-surface xCT quantification, GSH measurement, pharmacological inhibition (sulfasalazine), in vivo Sugen5416/hypoxia PAH model American journal of respiratory cell and molecular biology Medium 30897333
2022 Secreted AGR2 from tumor-associated neutrophils binds CD98hc as its functional receptor and increases xCT/SLC7A11 transporter activity in a CD98hc-dependent manner, subsequently activating RhoA/ROCK2 cascade to promote CRC metastasis. Co-IP (AGR2-CD98hc), neutrophil-specific Agr2 KO mice, xCT activity assay, RhoA/ROCK2 pathway analysis, in vivo liver metastasis model Gut Medium 35086885
2023 AhR (aryl hydrocarbon receptor) transcriptionally regulates SLC7A11 expression; pharmacological inactivation or genetic ablation of AhR suppresses SLC7A11 and enhances erastin-induced ferroptosis; the endogenous AhR ligand indole-3-pyruvate protects against ferroptosis through an AhR-SLC7A11 dependent mechanism. Post-translational modifications of SLC7A11 were also detected during ferroptosis. AhR KO/pharmacological inhibition, SLC7A11 transcription analysis, AhR ChIP (implied by transcriptional regulation), ferroptosis assays (lipid peroxidation), I3P supplementation Toxicology and applied pharmacology Medium 38641223
2024 PIAS4 directly binds SLC7A11 and facilitates its SUMOylation; KDM1A acts as a transcriptional activator of PIAS4; tanshinone IIA reduces KDM1A expression, thereby suppressing PIAS4 transcription, reducing SLC7A11 SUMOylation, and destabilizing SLC7A11 to promote ferroptosis in breast cancer. Ni-beads pull-down assay, Co-IP, luciferase assay, ChIP, SUMOylation assay, in vivo xenograft/lung metastasis models Journal of advanced research Medium 38615741
2023 Sulforaphane (SFN) directly targets p62 protein, enhancing p62-SLC7A11 protein-protein interaction, which promotes autolysosomal (lysosomal) degradation of SLC7A11 and triggers ferroptosis in osteosarcoma. p62-SLC7A11 Co-IP, lysosomal degradation inhibitor experiments, ferroptosis markers, in vivo subcutaneous and intratibial OS xenograft models Redox biology Medium 39657365
2023 RBM3 binds SLC7A11 mRNA; sodium butyrate promotes RBM3 expression, which indirectly downregulates SLC7A11 and promotes ferroptosis in endometrial cancer cells. RNA pulldown and mass spectrometry (RBM3-SLC7A11 mRNA), transcriptome analysis, metabolome analysis, in vivo xenograft Apoptosis Medium 37170022
2023 DUBA deubiquitinase stabilizes SLC7A11 protein in differentiated cells; elevated SLC7A11 in turn increases c-Myc expression through cysteine; undifferentiated (stem) cells express low DUBA/SLC7A11 and are more sensitive to ferroptosis. DUBA KD/OE, SLC7A11 ubiquitination assay, c-Myc expression analysis, cysteine supplementation rescue, sorafenib + c-Myc inhibitor combination assay Oncogene Medium 37537342
2024 FMRP promotes SLC7A11 expression via two mechanisms: (1) it catalyzes m6A modification of SLC7A11 mRNA in a METTL3-dependent manner, influencing translation; (2) FMRP interacts with splicing factor hnRNPM to modulate an exon-skip splicing event of SLC7A11 transcript, generating the SLC7A11-S variant that promotes ferroptosis resistance in breast cancer. RIP, METTL3-dependency analysis, Co-IP (FMRP-hnRNPM), splicing analysis, ferroptosis assays, clinical sample correlation Redox biology Medium 39388855
2025 METTL3 methylates adenine +1795 on SLC7A11 mRNA; the m6A reader IGF2BP2 recognizes this site and promotes SLC7A11 mRNA stability. Separately, METTL3 decreases SLC7A11 protein ubiquitination through the m6A/YTHDF2/SOCS2 axis. Both mechanisms require METTL3 methyltransferase activity. m6A site mapping (adenine +1795), RIP for IGF2BP2-SLC7A11 mRNA, mRNA stability assay, ubiquitination assay, SOCS2-YTHDF2 pathway analysis, in vivo HCC radiosensitivity models Cell death & disease Medium 39799112

Source papers

Stage 0 corpus · 100 papers · ranked by NIH iCite citations
Year Title Journal Citations PMID
2020 Cystine transporter SLC7A11/xCT in cancer: ferroptosis, nutrient dependency, and cancer therapy. Protein & cell 2013 33000412
2019 Radiotherapy and Immunotherapy Promote Tumoral Lipid Oxidation and Ferroptosis via Synergistic Repression of SLC7A11. Cancer discovery 875 31554642
2018 Amino acid transporter SLC7A11/xCT at the crossroads of regulating redox homeostasis and nutrient dependency of cancer. Cancer communications (London, England) 779 29764521
2020 Loss of Cardiac Ferritin H Facilitates Cardiomyopathy via Slc7a11-Mediated Ferroptosis. Circulation research 650 32349646
2021 Metformin induces Ferroptosis by inhibiting UFMylation of SLC7A11 in breast cancer. Journal of experimental & clinical cancer research : CR 326 34162423
2023 ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. Journal of hepatology 308 36996941
2020 xCT: A Critical Molecule That Links Cancer Metabolism to Redox Signaling. Molecular therapy : the journal of the American Society of Gene Therapy 291 32931751
2018 xCT (SLC7A11)-mediated metabolic reprogramming promotes non-small cell lung cancer progression. Oncogene 270 29789716
2022 SOCS2-enhanced ubiquitination of SLC7A11 promotes ferroptosis and radiosensitization in hepatocellular carcinoma. Cell death and differentiation 267 35995846
2021 RBMS1 regulates lung cancer ferroptosis through translational control of SLC7A11. The Journal of clinical investigation 265 34609966
2022 Targeting SLC7A11 improves efferocytosis by dendritic cells and wound healing in diabetes. Nature 242 35614212
2021 Induction of ferroptosis by ATF3 elevation alleviates cisplatin resistance in gastric cancer by restraining Nrf2/Keap1/xCT signaling. Cellular & molecular biology letters 237 34098867
2021 Stem Cell Factor SOX2 Confers Ferroptosis Resistance in Lung Cancer via Upregulation of SLC7A11. Cancer research 223 34385181
2022 The Role of Cystine/Glutamate Antiporter SLC7A11/xCT in the Pathophysiology of Cancer. Frontiers in oncology 205 35280777
2023 Baicalin induces ferroptosis in osteosarcomas through a novel Nrf2/xCT/GPX4 regulatory axis. Phytomedicine : international journal of phytotherapy and phytopharmacology 169 37209607
2022 STAT6 inhibits ferroptosis and alleviates acute lung injury via regulating P53/SLC7A11 pathway. Cell death & disease 164 35668064
2022 SLC7A11 as a Gateway of Metabolic Perturbation and Ferroptosis Vulnerability in Cancer. Antioxidants (Basel, Switzerland) 163 36552652
2022 The N6-methyladenosine modification enhances ferroptosis resistance through inhibiting SLC7A11 mRNA deadenylation in hepatoblastoma. Clinical and translational medicine 152 35522946
2022 PHGDH Inhibits Ferroptosis and Promotes Malignant Progression by Upregulating SLC7A11 in Bladder Cancer. International journal of biological sciences 145 36147463
2022 Kynurenine importation by SLC7A11 propagates anti-ferroptotic signaling. Molecular cell 136 35245456
2019 Regulation of H2A ubiquitination and SLC7A11 expression by BAP1 and PRC1. Cell cycle (Georgetown, Tex.) 119 30907299
2021 HBx facilitates ferroptosis in acute liver failure via EZH2 mediated SLC7A11 suppression. Journal of biomedical science 117 34615538
2022 SHARPIN promotes cell proliferation of cholangiocarcinoma and inhibits ferroptosis via p53/SLC7A11/GPX4 signaling. Cancer science 112 35968603
2023 TRIM3 facilitates ferroptosis in non-small cell lung cancer through promoting SLC7A11/xCT K11-linked ubiquitination and degradation. Cell death and differentiation 108 37978273
2022 Tumour-associated neutrophils secrete AGR2 to promote colorectal cancer metastasis via its receptor CD98hc-xCT. Gut 103 35086885
2023 Targeting USP8 Inhibits O-GlcNAcylation of SLC7A11 to Promote Ferroptosis of Hepatocellular Carcinoma via Stabilization of OGT. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 101 37867237
2023 Inhibiting the compensatory elevation of xCT collaborates with disulfiram/copper-induced GSH consumption for cascade ferroptosis and cuproptosis. Redox biology 90 38150993
2024 Role of SLC7A11/xCT in Ovarian Cancer. International journal of molecular sciences 89 38203758
2021 KDM4A-mediated histone demethylation of SLC7A11 inhibits cell ferroptosis in osteosarcoma. Biochemical and biophysical research communications 87 33689883
2021 SLC7A11/xCT Prevents Cardiac Hypertrophy by Inhibiting Ferroptosis. Cardiovascular drugs and therapy 85 34259984
2023 NFATc1-mediated expression of SLC7A11 drives sensitivity to TXNRD1 inhibitors in osteoclast precursors. Redox biology 82 37148740
2020 RNA binding protein DAZAP1 promotes HCC progression and regulates ferroptosis by interacting with SLC7A11 mRNA. Experimental cell research 81 33358859
2023 Arbutin alleviates fatty liver by inhibiting ferroptosis via FTO/SLC7A11 pathway. Redox biology 77 37984229
2011 Regulation of xCT expression and system x (c) (-) function in neuronal cells. Amino acids 73 21369940
2024 Targeting FTO induces colorectal cancer ferroptotic cell death by decreasing SLC7A11/GPX4 expression. Journal of experimental & clinical cancer research : CR 69 38600610
2022 The Role of SLC7A11 in Cancer: Friend or Foe? Cancers 68 35804831
2024 Xanthohumol ameliorates drug-induced hepatic ferroptosis via activating Nrf2/xCT/GPX4 signaling pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 65 38394733
2023 Resveratrol Alleviates Diabetic Periodontitis-Induced Alveolar Osteocyte Ferroptosis Possibly via Regulation of SLC7A11/GPX4. Nutrients 65 37432277
2024 AMPKα1-mediated ZDHHC8 phosphorylation promotes the palmitoylation of SLC7A11 to facilitate ferroptosis resistance in glioblastoma. Cancer letters 64 38211651
2024 Icariin inhibits chondrocyte ferroptosis and alleviates osteoarthritis by enhancing the SLC7A11/GPX4 signaling. International immunopharmacology 63 38636375
2024 Targeting SIRT3 sensitizes glioblastoma to ferroptosis by promoting mitophagy and inhibiting SLC7A11. Cell death & disease 62 38395990
2023 Cigarette tar mediates macrophage ferroptosis in atherosclerosis through the hepcidin/FPN/SLC7A11 signaling pathway. Free radical biology & medicine 57 36933812
2022 STEAP3 Affects Ferroptosis and Progression of Renal Cell Carcinoma Through the p53/xCT Pathway. Technology in cancer research & treatment 57 35275508
2023 Mangiferin attenuates osteoporosis by inhibiting osteoblastic ferroptosis through Keap1/Nrf2/SLC7A11/GPX4 pathway. Phytomedicine : international journal of phytotherapy and phytopharmacology 56 38176266
2023 Sodium butyrate induces ferroptosis in endometrial cancer cells via the RBM3/SLC7A11 axis. Apoptosis : an international journal on programmed cell death 51 37170022
2020 xCT (SLC7A11) expression confers intrinsic resistance to physical plasma treatment in tumor cells. Redox biology 50 31931281
2023 Ferroptosis and Neurodegenerative Diseases: Insights into the Regulatory Roles of SLC7A11. Cellular and molecular neurobiology 46 36988772
2024 SLC7A11: the Achilles heel of tumor? Frontiers in immunology 45 39040097
2023 Macrophages originated IL-33/ST2 inhibits ferroptosis in endometriosis via the ATF3/SLC7A11 axis. Cell death & disease 45 37816731
2024 α-Ketoglutarate alleviates osteoarthritis by inhibiting ferroptosis via the ETV4/SLC7A11/GPX4 signaling pathway. Cellular & molecular biology letters 41 38877424
2024 Augmented ERO1α upon mTORC1 activation induces ferroptosis resistance and tumor progression via upregulation of SLC7A11. Journal of experimental & clinical cancer research : CR 40 38610018
2023 EGCG alleviates obesity-exacerbated lung cancer progression by STAT1/SLC7A11 pathway and gut microbiota. The Journal of nutritional biochemistry 40 37451475
2021 EZH2-mediated SLC7A11 upregulation via miR-125b-5p represses ferroptosis of TSCC. Oral diseases 40 34614259
2023 SLC7A11 promotes the progression of gastric cancer and regulates ferroptosis through PI3K/AKT pathway. Pathology, research and practice 39 37399587
2024 Regulation of SLC7A11 as an unconventional checkpoint in tumorigenesis through ferroptosis. Genes & diseases 38 39569390
2023 CEBPG suppresses ferroptosis through transcriptional control of SLC7A11 in ovarian cancer. Journal of translational medicine 38 37210575
2024 Tanshinone IIA destabilizes SLC7A11 by regulating PIAS4-mediated SUMOylation of SLC7A11 through KDM1A, and promotes ferroptosis in breast cancer. Journal of advanced research 37 38615741
2023 SLC7A11-associated ferroptosis in acute injury diseases: mechanisms and strategies. European review for medical and pharmacological sciences 37 37259719
2025 SLC7A11 is an unconventional H+ transporter in lysosomes. Cell 36 40280132
2023 Glial Glutamate Transporter-Mediated Plasticity: System xc-/xCT/SLC7A11 and EAAT1/2 in Brain Diseases. Frontiers in bioscience (Landmark edition) 36 37005761
2023 The DUBA-SLC7A11-c-Myc axis is critical for stemness and ferroptosis. Oncogene 36 37537342
2024 SPTBN2 suppresses ferroptosis in NSCLC cells by facilitating SLC7A11 membrane trafficking and localization. Redox biology 35 38241838
2023 Nicorandil Regulates Ferroptosis and Mitigates Septic Cardiomyopathy via TLR4/SLC7A11 Signaling Pathway. Inflammation 32 38159178
2024 Berberine synergises with ferroptosis inducer sensitizing NSCLC to ferroptosis in p53-dependent SLC7A11-GPX4 pathway. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 31 38850659
2023 ALKBH5 decreases SLC7A11 expression by erasing m6A modification and promotes the ferroptosis of colorectal cancer cells. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 31 36820954
2023 The amino acid transporter SLC7A11 expression in breast cancer. Cancer biology & therapy 31 38073087
2019 Endothelial-Mesenchymal Transition Drives Expression of CD44 Variant and xCT in Pulmonary Hypertension. American journal of respiratory cell and molecular biology 30 30897333
2024 Gastrodin: Modulating the xCT/GPX4 and ACSL4/LPCAT3 pathways to inhibit ferroptosis after ischemic stroke. Phytomedicine : international journal of phytotherapy and phytopharmacology 29 39731833
2025 Nrf2 alleviates acute ischemic stroke induced ferroptosis via regulating xCT/GPX4 pathway. Free radical biology & medicine 28 40020881
2024 Essentiality of SLC7A11-mediated nonessential amino acids in MASLD. Science bulletin 28 39366830
2024 Deubiquitylase USP52 Promotes Bladder Cancer Progression by Modulating Ferroptosis through Stabilizing SLC7A11/xCT. Advanced science (Weinheim, Baden-Wurttemberg, Germany) 27 39392373
2024 Targeting p62 by sulforaphane promotes autolysosomal degradation of SLC7A11, inducing ferroptosis for osteosarcoma treatment. Redox biology 26 39657365
2023 Multiple myeloma with high expression of SLC7A11 is sensitive to erastin-induced ferroptosis. Apoptosis : an international journal on programmed cell death 25 38001343
2023 METTL9-SLC7A11 axis promotes hepatocellular carcinoma progression through ferroptosis inhibition. Cell death discovery 24 38017014
2024 Dihydroartemisinin induces ferroptosis of hepatocellular carcinoma via inhibiting ATF4-xCT pathway. Journal of cellular and molecular medicine 23 38652216
2024 SLC7A11 inhibits ferroptosis and downregulates PD-L1 levels in lung adenocarcinoma. Frontiers in immunology 22 38655266
2024 Berberine Inhibits Ferroptosis and Stabilizes Atherosclerotic Plaque through NRF2/SLC7A11/GPX4 Pathway. Chinese journal of integrative medicine 21 39167283
2024 LPCAT2 inhibits colorectal cancer progression via the PRMT1/SLC7A11 axis. Oncogene 20 38605214
2023 CIC reduces xCT/SLC7A11 expression and glutamate release in glioma. Acta neuropathologica communications 20 36647117
2025 METTL3 inhibition promotes radiosensitivity in hepatocellular carcinoma through regulation of SLC7A11 expression. Cell death & disease 19 39799112
2024 AhR signaling modulates Ferroptosis by regulating SLC7A11 expression. Toxicology and applied pharmacology 19 38641223
2024 Tumor suppressor BAP1 suppresses disulfidptosis through the regulation of SLC7A11 and NADPH levels. Oncogenesis 19 39266549
2023 Downregulation of lncRNA SLC7A11-AS1 decreased the NRF2/SLC7A11 expression and inhibited the progression of colorectal cancer cells. PeerJ 19 37077308
2025 Galectin-13 reduces membrane localization of SLC7A11 for ferroptosis propagation. Nature chemical biology 18 40246981
2024 Luteolin attenuates CCl4-induced hepatic injury by inhibiting ferroptosis via SLC7A11. BMC complementary medicine and therapies 18 38755566
2024 SLC7A11 in hepatocellular carcinoma: potential mechanisms, regulation, and clinical significance. American journal of cancer research 18 38859833
2023 The deubiquitinase ZRANB1 is an E3 ubiquitin ligase for SLC7A11 and regulates ferroptotic resistance. The Journal of cell biology 18 37831441
2023 SLC7A11, a potential immunotherapeutic target in lung adenocarcinoma. Scientific reports 18 37880315
2025 PRMT5 K240lac confers ferroptosis resistance via ALKBH5/SLC7A11 axis in colorectal cancer. Oncogene 17 40447754
2024 FMRP protects breast cancer cells from ferroptosis by promoting SLC7A11 alternative splicing through interacting with hnRNPM. Redox biology 17 39388855
2024 NINJ1 regulates ferroptosis via xCT antiporter interaction and CoA modulation. Cell death & disease 17 39424803
2024 Targeting SLC7A11/xCT improves radiofrequency ablation efficacy of HCC by dendritic cells mediated anti-tumor immune response. iMeta 17 39742309
2023 CTRP6 protects against ferroptosis to drive lung cancer progression and metastasis by destabilizing SOCS2 and augmenting the xCT/GPX4 pathway. Cancer letters 17 38084702
2025 SIK1 promotes ferroptosis resistance in pancreatic cancer via HDAC5-STAT6-SLC7A11 axis. Cancer letters 16 40250791
2024 Discovery of the Inhibitor Targeting the SLC7A11/xCT Axis through In Silico and In Vitro Experiments. International journal of molecular sciences 16 39125853
2023 Hsa_circ_0070440 promotes lung adenocarcinoma progression by SLC7A11-mediated-ferroptosis. Histology and histopathology 16 36852950
2025 LINC01088 prevents ferroptosis in glioblastoma by enhancing SLC7A11 via HLTF/USP7 axis. Clinical and translational medicine 15 40000422
2024 Chemerin attenuates acute kidney injury by inhibiting ferroptosis via the AMPK/NRF2/SLC7A11 axis. Communications biology 15 39702678
2023 NRF2 Antagonizes HIV-1 Tat and Methamphetamine-Induced BV2 Cell Ferroptosis by Regulating SLC7A11. Neurotoxicity research 15 37060393
2023 TXNDC12 knockdown promotes ferroptosis by modulating SLC7A11 expression in glioma. Clinical and translational science 15 37503932

Missed literature

Know a paper Affinage missed for SLC7A11? Flag it for the maintainers and the community.

No submissions yet.